Exemestane vs. tamoxifen after 2-3 years' tamoxifen

Article

-->

Switching to exemestane after 2 to 3 years of treatment with tamoxifen improves disease-free and overall survival in postmenopausal women with estrogen-receptor–positive early breast cancer, according to the results of a randomized, controlled trial from Europe.

Researchers included almost 5,000 women who had unilateral invasive disease but who were disease-free after 2 to 3 years of treatment with tamoxifen. Half the women were then switched to the aromatase inhibitor exemestane, while the other half continued taking tamoxifen for the remainder of 5 years.

After a median follow-up of 4.5 years, the unadjusted hazard ratio was 0.76 (95% CI, 0.66–0.88, P=0.0001) in favor of exemestane. The absolute benefit by the end of treatment was 3.3% (95% CI, 1.6–4.9). In terms of number of deaths, 222 occurred in the exemestane group versus 261 in the tamoxifen group.

Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-570.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Thomas McElrath, MD, PhD, highlights limitations of current preeclampsia guidelines | Image Credit: physiciandirectory.brighamandwomens.org.
Jane Varney, MD, discusses how a low FODMAP diet mediates gut symptoms caused by endometriosis | Image Credit: lens.monash.edu.
Ousseny Zerbo, PhD, highlights benefits of influenza vaccination during pregnancy | Image Credit: divisionofresearch.kaiserpermanente.org.
Michael Ussher, PhD, highlights the benefits of vaping over smoking in pregnancy | Image Credit: sgul.ac.uk.
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Related Content
© 2025 MJH Life Sciences

All rights reserved.